Cargando…

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

BACKGROUND: Interferon-induced expression of programmed cell death ligands (PD-L1/PD-L2) may sustain tumour immune-evasion. Patients featuring MET amplification, a genetic lesion driving transformation, may benefit from anti-MET treatment. We explored if MET-targeted therapy interferes with Interfer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Valentina, Chiriaco, Cristina, Modica, Chiara, Acquadro, Anna, Cortese, Marco, Galimi, Francesco, Perera, Timothy, Gammaitoni, Loretta, Aglietta, Massimo, Comoglio, Paolo M., Vigna, Elisa, Sangiolo, Dario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461865/ https://www.ncbi.nlm.nih.gov/pubmed/30723303 http://dx.doi.org/10.1038/s41416-018-0315-3

Ejemplares similares

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
por: Chiriaco, Cristina, et al.
Publicado: (2022)

A receptor-antibody hybrid hampering MET-driven metastatic spread
por: Modica, Chiara, et al.
Publicado: (2021)

hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
por: Martinelli, Ilaria, et al.
Publicado: (2022)

Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
por: Martinelli, Ilaria, et al.
Publicado: (2022)

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody
por: Modica, Chiara, et al.
Publicado: (2020)

MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk
por: Modica, Chiara, et al.
Publicado: (2018)

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
por: Sangiolo, Dario, et al.
Publicado: (2014)

Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination
por: Modica, Chiara, et al.
Publicado: (2023)

Revoking a Diploma
Publicado: (1860)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
por: Lin, Xiaoting, et al.
Publicado: (2019)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer
por: Modica, Chiara, et al.
Publicado: (2021)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Met–HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells
por: Stern, Yaakov E., et al.
Publicado: (2022)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy
por: Rotolo, Ramona, et al.
Publicado: (2019)

An Observatory for the MET Oncogene: A Guide for Targeted Therapies
por: Altintas, Dogus M., et al.
Publicado: (2023)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

MET Oncogene Controls Invasive Growth by Coupling with NMDA Receptor
por: Gallo, Simona, et al.
Publicado: (2022)

Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts
por: LIU, KAI, et al.
Publicado: (2015)

COVID-19 Pandemic: Significance of Lockdown and When to Revoke?
por: Shrivastava, Saurabh R., et al.
Publicado: (2022)

Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1(+) Chemoresistant Lung Cancer Cells
por: Rotolo, Ramona, et al.
Publicado: (2023)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
por: Kim, Nam Ah, et al.
Publicado: (2020)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis
por: Lazzari, Luca, et al.
Publicado: (2013)

HGF and MET: From Brain Development to Neurological Disorders
por: Desole, Claudia, et al.
Publicado: (2021)

MET Receptor Tyrosine Kinase Inhibition Reduces Interferon-Gamma (IFN-γ)-Stimulated PD-L1 Expression through the STAT3 Pathway in Melanoma Cells
por: Song, Kyu Young, et al.
Publicado: (2023)

The Met oncogene and basal-like breast cancer: another culprit to watch out for?
por: Gastaldi, Stefania, et al.
Publicado: (2010)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells
por: Gammaitoni, Loretta, et al.
Publicado: (2015)

Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models
por: Iaia, Ilenia, et al.
Publicado: (2021)

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
por: Petti, Consalvo, et al.
Publicado: (2014)

Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
por: Virzì, Anna Rita, et al.
Publicado: (2018)

Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
por: Ji, Fujian, et al.
Publicado: (2015)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Cai, Boning, et al.
Publicado: (2021)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells
por: Schroeder, Rebecca D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a8m6nntss4rcojo0md0vdu8mpm